Ryvu Therapeutics S.A. (WSE:RVU)
Poland
· Delayed Price · Currency is PLN 29.90
+1.15 (4.00%)
At close: Dec 5, 2025
Ryvu Therapeutics Revenue
Ryvu Therapeutics had revenue of 19.50M PLN in the quarter ending September 30, 2025, a decrease of -22.12%. This brings the company's revenue in the last twelve months to 90.41M, down -0.84% year-over-year. In the year 2024, Ryvu Therapeutics had annual revenue of 101.96M with 51.51% growth.
Revenue (ttm)
90.41M
Revenue Growth
-0.84%
P/S Ratio
7.65
Revenue / Employee
275.64K
Employees
328
Market Cap
691.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 101.96M | 34.67M | 51.51% |
| Dec 31, 2023 | 67.30M | -1.14M | -1.67% |
| Dec 31, 2022 | 68.44M | 33.02M | 93.25% |
| Dec 31, 2021 | 35.41M | -1.54M | -4.16% |
| Dec 31, 2020 | 36.95M | 3.23M | 9.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Diagnostyka | 2.30B |
| NEUCA | 13.34B |
| Synektik Spólka Akcyjna | 623.20M |
| Voxel | 568.83M |
| Celon Pharma | 225.60M |
| Selvita | 373.90M |
| Centrum Medyczne ENEL-MED | 820.59M |
| Scope Fluidics | 718.00K |